CSC 012-ADC
Alternative Names: CSC-012-ADCLatest Information Update: 28 Apr 2022
At a glance
- Originator Cellerant Therapeutics
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Myelodysplastic syndromes; Solid tumours
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (Parenteral)
- 28 Apr 2022 No recent reports of development identified for preclinical development in Myelodysplastic-syndromes in USA (Parenteral)
- 28 Apr 2022 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)